← Leaderboards
Shaker A Mousa
Vascular Vision Pharmaceuticals Company
$3,337,102
Attributed
$5,099,669
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $945.4K · FY2007–21$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,099,669 · 9
By mechanism
R44$3,238,189 · 2
R21$741,125 · 2
R41$502,714 · 3
R01$330,695 · 1
R43$286,946 · 1
Top collaborators
- Nabil A Elshourbagy4 shared
- Harold Vernon Meyers1 shared
Most similar at Vascular Vision Pharmaceuticals Company
Same institution · by research overlap
- Patricia G Phillips$300,000
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroCellsAdverse EffectsBasePharmaceutical PreparationsDoseLeadMouse ModelTumorCancer PatientSitePharmacologic SubstanceHeart DiseasesPlasmaNanoformulationChemotherapeutic AgentExhibitsNanoparticlePathway InteractionsPreventBloodLaboratoriesCancer Cell
Grant awards (13)
Oral PCSK9/LDLR antagonist direction to the clinic$945,393
R44 · FY2021 · HL
Oral PCSK9/LDLR antagonist direction to the clinic$943,895
R44 · FY2020 · HL
Improving Solubility, Stability and Permeability of Natural Products Extracts$286,946
R43 · FY2019 · AT
Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management$215,058
R41 · FY2019 · HL · contact PI
Development of Oral Small Molecule PCSK9 Antagonist$666,558
R44 · FY2018 · HL
Development of Oral Small Molecule PCSK9 Antagonist$682,343
R44 · FY2017 · HL
A mechanism for suppression of TNF induced endothelial dysfunction$330,695
R01 · FY2013 · HL · contact PI
Site-directed Chemotherapy for Breast Cancer using Novel Angiogenesis Inhibitor$203,280
R21 · FY2010 · CA · contact PI
Enabling high dose regional chemotherapy while minimizing systemic toxicity$159,306
R41 · FY2010 · CA · contact PI
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion$200,970
R21 · FY2009 · CA · contact PI
Site-directed Chemotherapy for Breast Cancer using Novel Angiogenesis Inhibitor$169,400
R21 · FY2009 · CA · contact PI
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion$167,475
R21 · FY2008 · CA · contact PI
Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer$128,350
R41 · FY2007 · CA · contact PI